Breaking News, Collaborations & Alliances

AGC Biologics, Trefoil Ink Manufacturing Deal

Trefoil selects AGC as lead manufacturer of TTHX1114 for treatment of corneal diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AGC Biologics, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Trefoil Therapeutics, have signed a manufacturing contract to supply their lead compound TTHX1114. Trefoil is developing products based on this engineered form of FGF-1 to restore lost vision in patients with corneal diseases by regenerating corneal tissue.   Trefoil Therapeutics selected AGC Biologics for their technical expertise and proven abilities in cGMP manufacture of protein-bas...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters